Germany’s statutory insurers generally cover colonoscopy and FIT for eligible adults. DNA-based stool tests are often self-pay unless a plan or pilot program opts in, which is why channel design matters. DoctorBox already supports both self-pay and reimbursed workflows and now lists ColoAlert, with samples processed by European Oncology Lab. If conversion and completion hold, reimbursement can follow adoption rather than lead it. The medical need is clear: CRC remains a top cancer killer, and pooled next-gen performance for the kit is competitive at \~92% CRC sensitivity, \~82% advanced adenomas, and \~95.8% high-grade dysplasia. MYNZ does not need a sales army if app nudges, clean logistics, and partner labs do the heavy lifting.
What to watch next: the share of DoctorBox orders reimbursed vs self-pay, average out-of-pocket, insurer pilot count and renewals, and days from claim to payment. If those tilt positive, Germany becomes a durable revenue leg while U.S. milestones line up.